Last reviewed · How we verify
NCT06960031
Added Value of PET/CT in Assessment of Hepatocellular Malignancy Post Radiofrequency Ablation
trial testing PET/CT technique in PET/CT in 70 participants. Completed in 30 April 2025.
30 April 2025
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 30 December 2024 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- PET/CT technique
Conditions studied
- PET/CT — all drugs for PET/CT →
- Hepatocellular Malignancy — all drugs for Hepatocellular Malignancy →
- Radiofrequency Ablation — all drugs for Radiofrequency Ablation →
Sponsor
Tanta University
Who can join
Adults 40 to 75, any sex, with PET/CT or Hepatocellular Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the residual tumoral activity versus the well ablation of اepatocellular carcinoma (HCC) post radiofrequency ablation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06960031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PET/CT
Currently open trials in the same condition.
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07242014 — 68Ga-XACP3 PET/CT in Prostate Cancer · NA · recruiting
- NCT07498933 — FAP-targeted PET/NIR in Lung Malignant Tumors · recruiting
- NCT07151898 — PET/CT for Trop2 ADC Response Evaluation NSCLC · recruiting
- NCT06756334 — Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis · EARLY_PHASE1 · recruiting
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06960031 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 20 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06960031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing